MedTrace Logo

Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants

NCT07093580 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2025-08-27

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.

Conditions

  • Healthy Participants

Interventions

DRUG

S-892216-LAI

S-892216-LAI injection will be administered per schedule specified in the arm description.

DRUG

Placebo

Physiological saline will be administered per schedule specified in the arm description.

Sponsors & Collaborators

  • Shionogi

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-29
Primary Completion
2027-05-26
Completion
2027-05-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07093580 on ClinicalTrials.gov